

FILLMED
LABORATOIRES



SMARTOUCH



ART FILLER®

HA DERMAL FILLERS

HAUTE-SCULPTURE CORRECTION

TRI-HYAL® + LIDOCAINE

ART FILLER®

HAUTE-SCULPTURE CORRECTION



FINE LINES



UNIVERSAL



VOLUME



LIPS SOFT



LIPS

TRI-HYAL® INNOVATION

3 HA - NATURAL FLEXIBLE ENTANGLING

3 hyaluronic acids, 3 correction potentials (sculpting, volumising, smoothing), optimal mouldability

EASY-TO-SHAPE TEXTURES

MATCHING EACH INJECTION SITE

Optimised texture tailored to match each injection site: superficial lines, lips, medium to deep wrinkles, volume restoration

HIGH PERFORMANCE & TOLERANCE

PROVEN OVER 18 MONTHS⁽¹⁾

Correction maintained and high tolerance was proven during the clinical evaluation.

Blind evaluation and instrument - based measurements⁽²⁾ (profilometry and dermal high-frequency ultrasound imaging)

OPTIMAL COMFORT

FOR OPTIMAL INJECTION EXPERIENCE

Products with lidocaine 0.3%, high injectability. Ergonomic syringe

MADE IN EUROPE: FILLMED MANUFACTURING

MAXIMAL QUALITY

International standards ISO 14 644, ISO 13 485

(1) ART FILLER® 1 study, 2014 a randomised comparative multicentric clinical trial on performance & safety of the filler ART FILLER® FINE LINES & UNIVERSAL on the crow's feet and nasolabial fold respectively based on clinical scoring and instrumental measures. (2) See pages 10-11.

ART FILLER®

TRI-HYAL® INNOVATION


NATURAL FLEXIBLE ENTANGLING

3 HYALURONIC ACIDS


1-VERY LONG CHAINS

+

2-LONG CHAINS




Network of natural flexible entangling
 > sculpting & volumising potentials




BDDE

3-FREE HYALURONIC ACID
 > smoothing potential

3 CORRECTION POTENTIALS



1-SCULPTING POTENTIAL
 EASY-TO-SHAPE: capacity of the gel to be sculpted



2-VOLUMISING POTENTIAL
 ELASTICITY: capacity of the gel to resist to stress



3-SMOOTHING POTENTIAL
 VISCOSITY: capacity of the gel to integrate smoothly into the tissues

ART FILLER®

A COMPLETE SHORT RANGE

TRI-HYAL®

WRINKLES



FINE LINES








UNIVERSAL

INDICATION	FINE AND SUPERFICIAL WRINKLES	MEDIUM TO DEEP WRINKLES
HA CONCENTRATION	20 mg/mL	25 mg/mL
RATIO: $\frac{\text{VERY LONG CHAINS}}{\text{LONG CHAINS}}$	●○○○	●●○○
CROSS-LINKING DEGREE	●○○○	●●●○
FREE HA	●●●●	●●●○
LIDOCAINE	0.3%	0.3%
PACKAGING	2 x 1 mL	2 x 1.2 mL
NEEDLES	4 x 30G½"	4 x 27G½"

INJECTION AREAS




VOLUME	LIPS	
 <p>VOLUME</p>	 <p>LIPS SOFT</p>	 <p>LIPS</p>
<p>VOLUME RESTORATION</p>	<p>PERIORAL WRINKLES SOFT VOLUME</p>	<p>LIP VOLUME</p>
<p>25 mg/mL</p>	<p>25 mg/mL</p>	<p>25 mg/mL</p>
<p>●●●●</p>	<p>●●○○</p>	<p>●●●○</p>
<p>●●●●</p>	<p>●●●○</p>	<p>●●●○</p>
<p>●○○○</p>	<p>●●●○</p>	<p>●●○○</p>
<p>0.3%</p>	<p>0.3%</p>	<p>0.3%</p>
<p>2 x 1.2 mL</p>	<p>1 x 1 mL</p>	<p>2 x 1 mL</p>
<p>4 x 27G½"</p>	<p>2 x 30G½"</p>	<p>4 x 27G½"</p>



ART FILLER®

TAILOR-MADE & EASY-TO-SHAPE TEXTURES



FINE LINES, UNIVERSAL, VOLUME, LIPS SOFT & LIPS



FINE LINES

SOFT & SMOOTHING


Fine and superficial wrinkles



UNIVERSAL

FILLING & SCULPTING


Medium to deep wrinkles



VOLUME

VOLUMISING & SHAPING

Volume creation & restoration



LIPS SOFT

SCULPTING & SMOOTHING

Perioral wrinkles and soft volume



LIPS

PLUMPING & DEFINING

Lip volume

ERGONOMIC BI-MATERIAL DESIGN FOR AN OPTIMISED INJECTION

EXCLUSIVE EXPERIENCE OF INJECTION

SMART DESIGN

Specifically developed to suit the needs and address the concerns of aesthetic practitioners.



BETTER INJECTION COMFORT

The syringe's texture provides a non-slip grip due to the soft touch material:

- more control
- more stability
- precise injection.

SAFER RETROASPIRATION

The comfort grips will:

- stabilise fingers.
- facilitate the retroaspiration when injecting.



ECO DESIGN SYRINGES

A PIONEERING TECHNOLOGY

AN ECO-SYRINGE MADE OF 1/3⁽¹⁾ OF SUSTAINABLE MATERIALS



SOFT TOUCH BIOPLASTIC

from renewable
biomass sources &
clean energy⁽²⁾

RECYCLED PLASTIC

from plastic bottles⁽³⁾

ENVIRONMENTAL IMPACT

-25.14%
of carbon impact

-3.12 tons
per year of plastic production

(1) Plunger and finger grip.

(2) At least 48%.

(3) At least 30%.

ART FILLER® UNIVERSAL

LONG-LASTING PERFORMANCE


PROVEN OVER 18 MONTHS

MAINTAINED CORRECTION OVER 18 MONTHS IN THE NLF

Scoring combined with profilometry



D0 before injection




D0 before injection

100% OF SUBJECTS⁽⁶⁾ STILL IMPROVED



At 12 months without re-injection




At 12 months without re-injection

98.4% OF SUBJECTS⁽⁶⁾ STILL IMPROVED



At 18 months



At 18 months

⁽⁶⁾ 31 subjects, 62 half-faces, evaluation of nasolabial fold with and without reinjections at 6 and/or 9 months by Lemprière scores at 12 and 18 months compared to D0 (independent evaluation by GREDECO), reduction of 1 point or more compared to the initial score.


ART FILLER®

PROVEN HIGH TOLERANCE


NO HYPERECHOGENIC RIM

Evaluation by Dermal High-Frequency Ultrasound


CROW'S FEET




D0 before injection



9 months



12 months with
re-injection at 9 months



18 months

SEEING IS BELIEVING

CLINICAL RESULTS FROM REAL PATIENTS



Before



After



Before



After



Before



After

SEEING IS BELIEVING

CLINICAL RESULTS FROM REAL PATIENTS



Before



After



Before



After



Before



After

ART FILLER®

Triple cross-linked hyaluronic acid based on Tri-Hyal Technique has more durable effect on dermal renewal

Chen R, Yang W, Sun J, et al. Clin Cosmet Investig Dermatol 2022;15:691-701



THIS STUDY SHOWS



That cross-linked AF with Tri-Hyal Technology consistently stimulates the dermal growth lasting for more than half year without efficiency attenuation

MATERIALS & METHODS

MATERIALS & METHODS	OBJECTIVES
<ul style="list-style-type: none">Mice were divided into three groups and treated with AFU, RES and a vehicle<ul style="list-style-type: none">→ Skin biopsies were taken on Day 0, 30, 90 and 180 after injection for histomorphometric evaluation, for evaluation of the dermal collagen synthesis and vascular densityHuman dermal fibroblast cells were incubated with AFU or RES and studied for:<ul style="list-style-type: none">→ Evaluation of their proliferation→ β-galactosidase analysis→ Autophagic flux detection→ The production of ROS	<ul style="list-style-type: none">Efficiency and persistence of AFU on skin rejuvenationInvestigation of underlying mechanisms

RESULTS

• **AFU with Tri-Hyal Technology provided dermal structural correction by improving skin thickness and elastic fiber formation**




No difference observed between two groups at D30.

AFU stimulated dermal growth and formation of elastic fiber as early as 30 days

HA injection promoted dermal thickness and elastic fiber formation, which peaked at D90

Dermal thickness and formation of elastic fiber were maintained up to 180 days after AFU treatment

- **AFU with Tri-Hyal Technology provided dermal structural correction by increasing vascular density and providing a durable effect on skin renewal**



Upregulation of TGF- β and downregulation of MMP, which are important markers of skin renewal, were observed with AFU*

- **AFU with Tri-Hyal Technology delayed the fibroblasts senescence *in vitro***

- AFU significantly **improved cell proliferation and viability** compared with RES
- AFU **significantly inhibited** β -galactosidase activity compared with RES

- **AFU with Tri-Hyal Technology reduced ROS levels in fibroblasts by inducing autophagy**

- AFU and RES **promoted autophagy** in fibroblasts
- AFU significantly **reduced ROS levels** in fibroblasts

SUMMARY OF KEY FINDINGS

EFFICACY


- **AFU WITH TRIPLE SUSTAINED-RELEASE CROSS-LINKING TRI-HYAL TECHNOLOGY PROVIDES PERSISTENT DERMAL STRUCTURAL CORRECTION IN DERMIS WITHOUT ANY ATTENUATION UP TO 6 MONTHS**
- **AFU COULD PROMOTE THE PROLIFERATION, VIABILITY AND ACTIVITY OF HUMAN PRIMARY FIBROBLASTS *IN VITRO*, WHICH WOULD BE MEDIATED BY CELLULAR AUTOPHAGY**

→ **AFU WITH THE TRIPLE SUSTAINED-RELEASE CROSS-LINKING TECHNOLOGY MAY HAVE A LONGER EFFECT ON SKIN REJUVENATION AND SLOW SKIN AGING**

*From D90 to D180, TGF- β expression began to decrease with RES, while still showing an upward trend with AFU. MMP9 expression levels were comparable between the two groups. HA= hyaluronic acid; AFU=Art Filler Universal; RES=Restylane II; ROS= reactive oxygen species; AFV=Art Filler Volume; JUV=Juv.derm Voluma

ART FILLER®

Comparative clinical study for the efficacy and safety of two different Hyaluronic Acid-based fillers with Tri-Hyal versus vycross technology: A long-term prospective randomised clinical trial



Braccini F, Fanian F, Garcia P, et al.
J Cosmet Dermatol 2022;00:1-13



EFFICACY



SAFETY



SATISFACTION

THIS STUDY CONFIRMS

The efficacy and safety of AFV vs JUV, with a sustained efficacy for at least 18 months


MATERIALS & METHODS

STUDY DESIGN	PRIMARY OUTCOME	SECONDARY OUTCOMES
<ul style="list-style-type: none"> A long-term prospective randomized clinical trial conducted to study the efficacy and safety of two different HA-based fillers (ART FILLER® Volume versus Juvéderm Voluma®) at D21, D90, D180, D270, D360, D450, and D540 A total of 98 male or female subjects (≥19 years old) 	<ul style="list-style-type: none"> Measurement of the restoration of the chin, midface, jawline, and temple volumes after a single injection (GACS, GAIS)* 	<ul style="list-style-type: none"> Assessment of skin characteristics by high-frequency ultrasound Analysis of the potential inflammation induced by the fillers on human skin explants (Assessment of IL-8, TNF-α, and histamine levels (ELISA)) Safety

RESULTS

• **AFV injection effectively restored the volumes of the chin, midface, jawline, and temple after 21 days**

REMANENCE OF GACS BETWEEN D0 AND D540 (PER PROTOCOL POPULATION)




- Each injected area started from grade 2 baseline (GACS) and was averagely reduced to: **1.2** for the midface, **1.3** for the jawline, **0.9** for the temple, **1.4** for the chin
- These significant reductions in GACS were maintained up to 540 days

98 subjects were enrolled in this study, 6 males and 92 females were included with an average age of 54.7 years old Mean±SD, ****p<0.0001, ***p<0.001 compared with D0 for each filler

- **High success rates were observed 3 weeks after AFV injection and maintained up to 18 months**


EVOLUTION OF THE SUCCESS RATE [% OF SUBJECTS FOR WHOM THE INITIAL GACS SCORE WAS REDUCED FROM ONE GRADE]



No significant difference between products was observed. These results were obtained without any touch-up injection during the whole study.

- **Patients were satisfied with AFV treatment**

GAIS ASSESSED BY THE SUBJECTS FROM D21 TO D540



No significant difference between products was observed.

The overall impression of the investigators was correlated to that of the subjects

SUMMARY OF KEY FINDINGS

EFFICACY	SAFETY	SATISFACTION
<ul style="list-style-type: none"> → NON-INFERIORITY OF AFV VERSUS JUV, THE REFERENCE PRODUCT, ON THE DIFFERENT INJECTED AREAS → INCREASE IN SKIN DENSITY WAS MORE RELEVANT WITH AFV THAN WITH JUV 	<ul style="list-style-type: none"> → NO RECORD OF SERIOUS ADVERSE EVENTS 	<ul style="list-style-type: none"> → HIGH SATISFACTION RATES
<p>→ THE POSSIBLE REASON FOR THE HIGHER EFFECT OF THE AFV MAY BE DUE TO THE TRI-HYAL TECHNOLOGY, WHICH PROVIDES A GOOD VISCOSITY THANKS TO FREE HA WITHIN THE COMPOSITION</p>		

HA= hyaluronic acid; AFV=Art Filler Volume; JUV=Juv.derm Voluma; GACS=Global Aesthetic Clinical Scoring; GAIS= Global Aesthetic Improvement Scale
*except for chin where only AFV was injected

ART FILLER®

A prospective multicenter clinical trial evaluating the efficacy and safety of a hyaluronic acid-based filler with Tri-Hyal technology in the treatment of lips and the perioral area



Ehlinger-David A, Gorj M, Braccini F, et al. J Cosmetic Dermatol 2022;00:1-9



THIS STUDY DEMONSTRATES

High efficacy and safety of AFL in the treatment of lips and the perioral area

MATERIALS & METHODS

STUDY DESIGN	PRIMARY OUTCOME	SECONDARY OUTCOMES
<ul style="list-style-type: none"> A prospective, multi-center trial to evaluate efficacy, longevity, and safety of a cross-linked HA-based filler with Tri-Hyal technology (AFL) in the treatment of lips, nasolabial folds, and marionette lines up to 18 months A total of 100 male or female subjects (≥19 years old) 	<ul style="list-style-type: none"> Esthetic correction 3 weeks after one injection session without touch-up (GAS) 	<ul style="list-style-type: none"> Esthetic correction without touch-up at D90, D180, D270, D360, D450, and D540 (GAIS) Safety

RESULTS

- AFL significantly improved the esthetics of lips, nasolabial folds, and marionette lines 21 days after injection, with a long-term sustained effect

GLOBAL AESTHETIC CLINICAL SCORE (PER PROTOCOL POPULATION) (BETWEEN BASELINE AND D21, AND BASELINE AND D450)


	LIPS			NASOLABIAL FOLDS			MARIONETTE LINES		
	D0	D21	D450	D0	D21	D450	D0	D21	D450
N		25			61			34	
SUCCESS (AT LEAST -1 GRADE VS D0)*, %		73.5	33		98.4	91		94.4	88

[Adapted from Ehlinger-David A, et al. 2022] *+1 grade for the lips

- With **98.4%**, success rates at D21 were highest for nasolabial folds ($p < 0.0001$)
 → Marionette lines: **94.4%**
 → Lips: **73.5%**
- Better long-term results** were observed with subjects injected into **nasolabial folds**

- AFL significantly increased dermal density in nasolabial folds up to 18 months after injection


DERMAL DENSITY MEASURED IN NASOLABIAL FOLDS USING HIGH FREQUENCY ULTRASOUND IMAGING



- Density was highest at D90 (**50.9%**) and decreased continuously up to 540 days (**46.6%**)

- **Both subjects and physicians indicated high levels of satisfaction 3 weeks after AFL injection**

— SUBJECTS
— INVESTIGATORS



Values are shown as the % total of subjects that improved compared to D0

- **AFL was well tolerated, and safety findings were consistent with those previously observed**

→ Most frequent adverse events (AE) included: Swelling: 82% (23/28) - Hematoma: 64% (18/28) - Pain: 43% (12/28)
 → All these AEs were resolved in several days/weeks

SUMMARY OF KEY FINDINGS

EFFICACY	SAFETY	SATISFACTION
→ AFL DEMONSTRATED HIGH EFFICACY AND SAFETY IN THE RESTORATION OF LIPS VOLUME AND TREATMENT OF NASOLABIAL FOLDS, AND MARIONETTE LINES	→ NO RECORD OF SERIOUS ADVERSE EVENTS	→ HIGH SATISFACTION RATES FOR NASOLABIAL FOLDS
→ AFL WITH THE TRIPLE SUSTAINED-RELEASE CROSS-LINKING TECHNOLOGY INDUCES EFFECTIVE STRUCTURAL TISSUE REMODELING		

HA= hyaluronic acid; AFL=Art Filler Lips; GAS=Global Aesthetic Score; GAIS= Global Aesthetic Improvement Scale
 *Success rates were consistent with results from the ITT population (Nasolabial folds: 95.5%; Marionette lines: 88.6%; Lips: 73.5%)

ART FILLER®

Hyaluronic acid fillers in facial contouring:
The “less is more” concept

Braccini F, Erfan N, Fanian F H. J Cosmet Dermatol 2021;5(5):113-117



THIS STUDY SHOWS

That the “less is more” technique for ha fillers in facial contouring optimizes natural results

MATERIALS & METHODS

STUDY DESIGN	OBJECTIVES
<ul style="list-style-type: none"> • Study conducted over a period of 30 months on a total of 162 patients divided into two age groups (1: 20-34 years and group 2: 35-50 years) • Global Aesthetic Improvements Scale (GAIS) was rated by the patients and physicians after treatment with cross-linked HA (Art Filler® Range, Fillmed) using the “less is more” technique 	<ul style="list-style-type: none"> • To study the efficacy of the “less is more” technique that limits the number of syringes and maximizes natural esthetic results via GAIS questionnaire

RESULTS

• **Almost all patients were satisfied with their HA-filler treatment**

PATIENT SATISFACTION SCALE ACCORDING TO THE AGE GROUP AND NUMBER OF INJECTED SYRINGES

		WORSENERD - 1	NO CHANGE 0	VISIBLE IMPROVED+1	TOTAL
Groupe 1	1 syringe	0	12.5% (n=2)	87.5% (n=14)	16
	2 syringes	0	0	100% (n=48)	48
Groupe 2	2 syringes	0	0	100% (n=49)	49
	3 syringes	0	0	100% (n=49)	49
Total		0	1.2% (n=2)	98.8% (n=160)	162

98.8% of the patients were satisfied with their treatment

Both groups experienced an **overall improvement in self-esteem and better self-perception**

• Physicians were satisfied with the “less is more” technique for HA fillers

PHYSICIAN SATISFACTION SCALE ACCORDING TO THE AGE GROUP AND NUMBER OF INJECTED SYRINGES

		NO CHANGE 0		MINIMAL IMPROVEMENT 1		MILD IMPROVEMENT 2		VISIBLE IMPROVEMENT 3		SIGNIFICANT IMPROVEMENT 4		TOTAL
		PH1	PH2	PH1	PH2	PH1	PH2	PH1	PH2	PH1	PH2	
Groupe 1	1 syringe	0	0	0	0	0	62% (1)	25% (4)	31.3% (5)	75% (12)	62.5% (10)	100% (16)
	2 syringes	0	0	0	0	0	0	0	16.7% (8)	100% (48)	83.3% (40)	100% (48)
Groupe 2	2 syringes	0	0	0	0	0	0	16.3% (8)	30.6% (15)	83.7% (41)	69.4% (34)	100% (49)
	3 syringes	0	0	0	0	0	0	0	14.3% (7)	100% (49)	85.7% (42)	100% (49)
Total		0	0	0	0	0	0.6% (1)	7.4% (12)	21.6% (35)	92.6% (150)	77.8% (126)	100% (162)

100% and 99.4% of patients had the visible and significant improvement according to the first and second evaluator, respectively

VISUAL EVIDENCE

<p>BEFORE</p> 	<p>AFTER</p> 	<p>BEFORE</p> 	<p>AFTER</p> 
<p>A 34-year-old patient of group 1 needs the enhancement of the highlighting point.</p>		<p>A 48-year-old patient of group 2 seeking volume restoration treatment to defy the effects of time and gravity, treated with 2.4 ml of HA Filler.</p>	

SUMMARY OF KEY FINDINGS

SATISFACTION

→ HIGH SATISFACTION RATES AMONG PATIENTS AND PHYSICIANS

→ HA FILLERS ARE EFFECTIVE AS A DURABLE TOOL FOR ENHANCING THE NATURAL LIGHT REFLECTING AREAS OF THE FACE IN PATIENTS AGED 20-50 VIA THE ‘LESS IS MORE’ TECHNIQUE

HA= hyaluronic acid; PH=physician; The 'less is more' concept is a global approach including the medical highlighting technique, the treatment of the negative zone of the face, and restoring facial volumes and contours.

ART FILLER®

A hyaluronic acid-based filler reduces lipolysis
In human mature adipocytes and maintains
adherence and lipid accumulation of long-term
differentiated Human preadipocytes

Nadra K, André M, Marchaud E, et al.
J Cosmet Dermatol 2021;20(5):1474-1482



THIS *IN VITRO* STUDY ADDS

To increasing body of evidence on the beneficial role of cross-linked ha-based fillers
in maintenance of the subcutaneous fat mass


MATERIALS & METHODS

MATERIALS & METHODS	OBJECTIVES
<ul style="list-style-type: none">• Culture of isolated adipocytes and precursors cells from human skin donors• Treatment with cross-linked HA<ul style="list-style-type: none">→ Measurement of the lactate dehydrogenase (LDH) released by the preadipocytes (Fluorescent assay) and measurement of the number of viable cells (MTS proliferation assay) to study cytotoxic effects of cross-linked HA→ Quantification of intracellular lipid accumulation after staining of lipid droplets by BODIPY and cells nuclei by DAPI (acquisition and image processing) to assess the maintenance preadipocyte differentiation→ Measurement of glycerol release to assess lipolytic activity in adipocytes	<ul style="list-style-type: none">• Cytotoxic effects of cross-linked HA on human preadipocytes• Maintenance of preadipocyte differentiation• Lipolytic activity measurement in adipocytes

RESULTS

• Cross-linked HA-based filler was not cytotoxic for human preadipocytes

DOSE RESPONSE EFFECTS OF CROSS-LINKED HA ON LDH ACTIVITY



- The different cross-linked HA concentrations tested (0.02%; 0.04%; 0.08%; 0.16%; 0.3%) showed **no cytotoxic effect** compared to the basal medium (DMEM 1% SVF)
- The **viability of human preadipocytes** treated with cross-linked HA **was not altered**

LDH activity was measured from extracellular medium of 7 days differentiated preadipocytes

• Cross-linked HA-based filler maintained human preadipocytes differentiation


→ Preadipocytes maintained their capacities to **accumulate lipid droplets** in presence of HA

• Cross-linked HA promoted cell adherence

→ Cross-linked HA **prevented loss of adherence** in a dose-dependent manner during prolonged culture

- **Cross-linked ha significantly reduced lipolysis in mature adipocytes**

PREVENTION OF LIPOLYSIS* IN HUMAN MATURE ADIPOCYTES




- Cross-linked HA had **beneficial effects** in the late phase of the preadipocytes differentiation (mature adipocytes)

*induced by isoproterenol
 (A) Basal and isoproterenol 1 $\mu\text{mol/L}$ stimulated (B) lipolysis of cultured mature adipocytes treated or no with HA

- **Cross-linked HA could reduce the cellular stress and the proinflammatory cytokine secretion by the adipocytes, promoting cell adherence and reducing lipolysis**

SCHEMATIC REPRESENTATION OF THE POTENTIAL ROLE OF CROSS-LINKED HA ON PREADIPOCYTE BEHAVIOR DURING THE ADIPOGENESIS PROCESS AND ADIPOCYTE METABOLISM



SUMMARY OF KEY FINDINGS

EFFICACY









- CROSS-LINKED HA **REDUCES LIPOLYSIS** IN FULLY MATURE ADIPOCYTES
- CROSS-LINKED HA **PROMOTES CELL PROLIFERATION AND ADHERENCE**
- CROSS-LINKED HA **PRESERVES THE ADIPOGENIC CAPACITY** OF PREADIPOCYTES DURING PROLONGED CELL CULTURE *IN VITRO*

HA= hyaluronic acid; AFU=Art Filler Universal; AFFL=Art Filler Fine lines; LDH=lactate dehydrogenase; PA=preadipocytes; ISO=isoproterenol
 *Induced by isoproterenol.

TAILOR-MADE SOLUTIONS

FILMED SIGNATURE PROTOCOLS

OPTIMISED PROTOCOLS TO RESPECT THE SINGULARITY OF EACH PATIENT.

CLINICAL ALGORITHM TO DECIDE ON A PROTOCOL	PROTOCOLS		PRODUCTS
RADIANCE		BIONUTRIGLOW	PEEL + TOPICAL POLYREVITALISING SOLUTION + SKIN CARE
EYE		BEAUTIFEYE	PEEL + POLYREVITALISING SOLUTION with specific device + SKIN CARE
NECK		BIONUTRINECK	
SKIN BOOSTER EFFECT		BIONUTRILIFT®	POLYREVITALISING SOLUTION + DERMAL FILLERS
		BIONUTRILIPS	
FACE SHAPING		BIONUTRISHAPE	POLYREVITALISING SOLUTION + DERMAL FILLERS
FACIAL HIGHLIGHT		MEDICAL HIGHLIGHTING®	ONLY DERMAL FILLERS
		2.4 PRO D-LIGHT	



BEAUTY IS AN ART, WE MADE IT A SCIENCE



SCAN & VISIT

uk.fillmed.com

Tel. : 0800 999 1685 - Email : info.uk@fillmed.com